Intas launches Romiplostim in India, an affordable treatment for Chronic Immune Thrombocytopenia
- by Team ABLE - 10 Jul, 2019
Intas Pharmaceuticals has announced that the company has taken a revolutionary step towards making therapy for chronic immune thrombocytopenia (ITP) more accessible to patients by being the first to launch Romiplostim inIndiaunder the name Romy.
Intas has said in its press statement that Romiplostim is one of the most efficacious agents with proven long-term benefits in chronic ITP. It represents the standard of care but has been available only internationally since 2008. It is estimated that around 42,000 patients are diagnosed with ITP inIndiaevery year. Less than 10% of patients which include adults as well as children, have access to the treatment which is required to maintain adequate platelet counts for a longer duration. In ITP, long term use of drugs is required to maintain adequate platelet count.
The press statement further said that the currently available standard of care therapy for chronic ITP costs approximately~Rs.60,000 per month, which can financially drain most patients. Hence, there was an unmet need for a drug like Romiplostim, which is accessible to the majority of patients and gives one of the best responses amongst the available treatment options. To fulfil this unmet need, Intas Pharmaceuticals Ltd. introduces Romiplostim for thefirst time inIndia, with the brand name Romy. With the launch of Romy, which is priced at Rs. 2,995 for a dose of 250 mcg, the monthly cost of treatment for most patients will be less thanRs.12,000, a huge relief to the chronic ITP patients across the country.
Dr.Mammen Chandy, Director of Tata Medical Center,Kolkataand Padma Shri award winner, shared his views on this landmark launch, saying, “Romiplostim's introduction in India will help clinicians immensely as it will add to their therapeutic armamentarium in managing thrombocytopenia due to Chronic ITP and Bone Marrow failure. Even in patients developing hepatotoxicity due to Eltrombopag, Romiplostim will be considered as a choice of treatment.”
Talking more about the launch, Dr. MB Agarwal, one of the leading haematologists in the country, said, “Romiplostim is an injection given below the skin (like insulin) once a week which was available in U.S.,EuropeandAustraliafor almost a decade but was never marketed inIndia. Patients were using an oral pill - Eltrombopag on a daily basis at the cost of almost 2,750 per day. With Intas, Romiplostim's cost for treating chronic ITP will come down by almost six times. Approved for ITP, this drug may be used by clinicians as per their discretion for managing low platelet counts due to other reasons as well.”
Intas Pharmaceuticals Ltd. introduces Romiplostim for the first time in India, with the brand name Romy.